Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 AM EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 AM EST. The presentation will feature CEO John Valliant, CFO John Crowley, and CMO James O'Leary. Attendees can access a live webcast on the company's website, with a replay available for 90 days. Fusion focuses on developing next-generation radiopharmaceuticals, using its proprietary Fast-Clear linker technology to target tumors selectively. The lead program, FPI-1434, is currently undergoing a Phase 1 clinical trial.
Details
News Market Reaction – FUSN
The recorded move for FUSN in the trading session of this news was -2.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30am EST / 1:30pm GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., Chief Financial Officer John Crowley, and Chief Medical Officer James O'Leary, M.D.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors and Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.
View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-301172266.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.